GlassScriptPhysician profile
Josephine Mei
NPI 1700815586
$100,588.32
in general payments reported to CMS, 2019-2025
29 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $21K · 2021: $7,503 · 2022: $24K · 2023: $12K · 2024: $265 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,546 · Food and Beverage: $1,892 · Travel and Lodging: $1,663 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,546.00 |
| Food and Beverage | $1,892.47 |
| Travel and Lodging | $1,663.49 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $56,721.48 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36,410.03 | 2021-2023 | Glassia |
| Astrazeneca Pharmaceuticals LP | $4,055.23 | 2019-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $643.93 | 2019-2025 | |
| Inspire Medical Systems, INC. | $304.37 | 2022-2024 | Inspire |
| Pulmonx Corporation | $222.22 | 2019-2020 | |
| Insmed, INC. | $213.07 | 2019-2020 | |
| Harmony Biosciences LLC | $181.33 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.29 | 2019 | |
| Grifols Shared Services North America, INC. | $172.30 | 2024-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $171.58 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $140.66 | 2023-2024 | Quviviq |
| Zoll Respicardia, INC. | $130.38 | 2025 | Remede System |
| Genzyme Corporation | $121.86 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $119.70 | 2025 | Lumryz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.26 | 2025 | |
| Verona Pharma, INC. | $102.82 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $94.50 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $88.96 | 2019-2020 | |
| Philips North America LLC | $73.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $67.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.62 | 2019-2020 | |
| United Therapeutics Corporation | $60.51 | 2021 | |
| Genentech USA, INC. | $38.00 | 2019 | |
| Grifols USA, LLC | $26.58 | 2019 | |
| Advanced Respiratory, INC | $25.22 | 2019 | |
| Circassia INC. | $18.76 | 2019 | |
| Fisher & Paykel Healthcare INC | $15.61 | 2024 | Fisher & Paykel Healthcare |
| Shire North American Group INC | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Mei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.